Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews

Executive Summary

Herceptin and Rituxan biosimilar applications expected to reach FDA early next year while EMA review is ongoing; timing could be another test for 351(k) pathway in US.


Related Content

2016 Review: Mixed Bag Of Hope, Setbacks For Korean Pharma
Pfizer's Herceptin Biosimilar Moving Forward Amid Rising Competition
Biosimilars: The Unlikely Hero Of Specialty Pharma?
Inflectra Launch Prep Continues Post-Deadline, Pfizer Says
Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates
Samsung Enters Oncology as Trastuzumab Accepted For EU Review
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Biosimilar User Fee Reboot: Resource Challenges Make FDA Eye New Structure
Neupogen Off-Label Use Complicates Data Extrapolation For Sandoz’s Biosimilar


Related Companies